Skip Navigation

European Heart Journal 1997 18(Supplement F):17-21; doi:10.1093/eurheartj/18.suppl_F.17
Copyright © 1997 by the European Society of Cardiology.
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Bode, C.
Right arrow Articles by Weaver, W. D.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Bode, C.
Right arrow Articles by Weaver, W. D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1997 The European Society of Cardiology

Clinical trial results with a new plasminogen activator

C. Bode*,, K. Peter*, M. Moser*, R. W. Smalling{dagger} and W. D. Weaver{ddagger}

* Medizinische Klinik III (Kardiologie), Universitat Heidelberg Germany
{dagger} Division of Cardiology, University of Texas Medical School Houston, Texas
{ddagger} Division of Cardiology, Henry Ford Health System Detroit, Michigan

Correspondence: Christoph Bode, MD, Medizinische Klinik III (Kardiologie), Bergheimerstrasse 58, 69115 Heidelberg, Germany

Thrombolysis has become an accepted form of therapy for acute myocardial infarction. As demonstrated in the Global Utilization of Streptokinase and t-PA for Occluded Arteries trial, early, complete and sustained patency of the infarctrelated coronary artery is correlated with reduced mortality. However, current thrombolytic regimens are able to achieve such patency within 90 min in only 81% of cases. To improve the risk/benefit ratio of thrombolytic therapy, newer agents such as reteplase have been developed to establish more rapid, more complete and more stable coronary artery patency, thus reducing mortality.

This report summarizes the pharmacological properties of reteplase. It also summarizes the findings from various animal and clinical studies in which reteplase was compared with alteplase and streptokinase and the findings from animal and clinical studies evaluating infusion, single-bolus, and double-bolus doses of reteplase.

Key Words: Reteplase • r-PA • thrombolytics • patency • alteplase • t-PA • streptokinase • acute myocardial infarction


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.